Table 1.

Ongoing clinical trials in MCC (http://ClinicalTrials.gov).

NCT identifier	Title	Phase	Intervention
NCT03071406	Randomized Study of Nivolumab + Ipilimumab ± SBRT for Metastatic Merkel Cell Carcinoma	2	Nivolumab Ipilimumab SBRT
NCT02643303	A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects with Advanced, Measurable, Biopsy-Accessible Cancers	1/2	Durvalumab Tremelimumab Poly ICLC
NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-Associated Tumors (CheckMate358)	1/2	Nivolumab Ipilimumab BMS-986016 Daratumumab
NCT02584829	Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab with or without Cellular Adoptive Immunotherapy in Treating Patients with Metastatic Merkel Cell Carcinoma	1/2	Avelumab Merkel cell polyomavirus TAg-specific polyclonal autologous CD8-positive T cells Interferon beta, RT
NCT03271372	Adjuvant Avelumab in Merkel Cell Cancer (ADAM)	3	Avelumab
NCT02196961	Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma with Immune Checkpoint Blocking Antibodies Versus Observation (ADMEC-O)	2	Ipilimumab Nivolumab